微生物厌氧发酵

Search documents
 华恒生物:实现微生物厌氧发酵规模化生产L-缬氨酸产品,多个生产基地项目稳步推进
 Cai Jing Wang· 2025-10-15 03:13
 Core Insights - The company has achieved a technological breakthrough in anaerobic fermentation, leading to a 50% reduction in the production cost of L-Alanine [1] - The company has successfully implemented large-scale production of L-Valine through anaerobic fermentation, marking an international first [1] - Despite revenue growth in the first half of 2025, the company's net profit attributable to shareholders has declined year-on-year due to increased operational costs and market price drops for L-Valine [1]   Group 1 - The company has constructed a microbial cell factory for the anaerobic fermentation of L-Valine using renewable glucose as a raw material [1] - The company is actively addressing market demand and competition, resulting in a sustained increase in core product sales volume [1] - The company has reported ongoing projects, including the production of succinic acid and 1,3-propanediol at various bases [2]   Group 2 - The company emphasizes the green and cost advantages of its bio-based 1,3-propanediol production and is pushing for its application in PTT fibers [2] - The company is increasing investment in the industrialization of bio-based new material monomers, collaborating with Donghua University to establish a joint laboratory [2] - The company is leading the formation of a bio-based polyester textile industry alliance to promote the marketization of 1,3-propanediol in various fields [2]
